Orf virus (ORFV) infects sheep and goats and is also an important zoonotic pathogen. The viral 17 protein OV20.0 has been shown to suppress innate immunity by targeting the double-stranded RNA 18 (dsRNA)-activated protein kinase (PKR) by multiple mechanisms. These mechanisms include a 19 direct interaction with PKR and binding with two PKR activators, dsRNA and the cellular PKR 20 activator (PACT), which ultimately leads to the inhibition of PKR activation. In the present study, 21
(ADAR1). OV20.0 bound directly to the dsRNA binding domains (RBDs) of ADAR1 in the 23 absence of dsRNA. Additionally, OV20.0 preferentially interacted with RBD1 of ADAR1, which 24 was essential for its dsRNA binding ability and for the homodimerization that is critical for intact 25 adenosine (A)-to-inosine (I) editing activity. Finally, the association with OV20.0 suppressed the 26 A-to-I editing ability of ADAR1, while ADAR1 played a proviral role during ORFV infection by 27 inhibiting PKR phosphorylation. These observations revealed a new strategy used by OV20.0 to 28 evade antiviral responses via PKR. 29 30 Importance (150 words) 31
Viruses evolve specific strategies to counteract host innate immunity. ORFV, an important zoonotic 32 pathogen, encodes OV20.0 to suppress PKR activation via multiple mechanisms, including 33
Introduction 45
Orf virus (ORFV), which belongs to the Parapoxvirus genus of the Poxviridae family, causes 46 contagious ecthyma, mainly in sheep, goats, and other ruminants (1). In addition, humans are 47 susceptible to ORFV and often infected by direct contact with infected animals. Previous studies 48 suggest that ORFV encodes several gene products that can manipulate cellular antiviral responses 49
(2). The OV20.0 protein, an ortholog of E3 from vaccinia virus (VACV), is an ORFV virulence 50 factor, by which ORFV subverts host innate immunity and thus establishes efficient replication (3, 51 4). OV20.0 contains two binding domains, including a Z-DNA binding domain at the N terminus 52 and a double-stranded RNA binding domain (RBD) at the C terminus (5). Furthermore, the 53 OV20.0L gene encodes two isoforms, a full-length OV20.0 and an N-terminally truncated short 54 form (sh20). Although the cellular distributions of these proteins differ, both OV20.0 isoforms have 55 similar functions, such as binding dsRNA, interacting with double-stranded RNA (dsRNA)-56 activated protein kinase (PKR) and inhibiting PKR phosphorylation (5). 57
Multiple strategies that are used by OV20.0 to suppress PKR activation were revealed recently (5, 58 6). OV20.0 is able to associate with PKR and compete with two cellular activators of PKR, i.e., 59 dsRNA and PACT. OV20.0 is a dsRNA binding protein (DRBP) that sequesters dsRNA and 60 therefore prevents PKR activation (5). In addition, the interaction between OV20.0 and the RBDs 61 of PKR arrests PKR phosphorylation by reducing the ability of dsRNA to bind to this region. This 62 physical association also occupies the binding site for PACT in the RBD2 and kinase domains of 63 5 PKR. Another possible mechanism is that OV20.0 forms heterodimers with PACT via their RBDs, 64 which may further reduce PACT-dependent PKR activation (6) . 65
Adenosine deaminase acting on RNA (ADAR), which is also a DRBP, converts adenosines (A) 66 into inosines (I) in cellular and viral dsRNA through its deaminase activity. This reaction is referred 67 to as A-to-I RNA editing (7, 8) . Inosine is recognized as guanine in RNA duplexes, and A-to-I RNA 68 editing may thus change the sequence and structure of RNA, leading to genetic recoding and the 69 destabilization of RNA. In mammalian cells, the ADAR family includes ADAR1, ADAR2 and 70 ADAR3; among those proteins, ADAR3 is catalytically inactive even though it contains a putative 71 catalytic domain (9). Due to alternative promoter usage, the ADAR1 gene is transcribed into two 72 isoforms (10) known as p150 and p110; p150 harbors a consensus sequence for the IFN-stimulated 73 response element (ISRE) that places p150 expression under the control of IFN (11), while p110 is 74 constitutively expressed. The p110 protein is an N-terminally truncated version of p150, and the 75 two ADAR1 isoforms contain either one (i.e., p110) or two (p150) Z-DNA binding domains at the 76 N-terminus, adjacent to three copies of the RBD (R1, R2 and R3) (12). In addition, both forms of 77 ADAR1 have a deaminase catalytic domain at their C-terminus. Moreover, the cellular distribution 78 of the two ADAR1 isoforms is distinct; p150 is present throughout the cell, while p110 is largely 79 localized in the nucleus (13, 14) due to the lack of a nuclear export signal (NES). 80
Although ADAR1 p150 is an IFN-inducible gene, increasing evidence indicates a proviral role of 81 ADAR1. This protein enhances viral replication, particularly for RNA viruses, by at least two 82 6 mechanisms: RNA editing and PKR inhibition (15, 16). For example, the overexpression of 83 ADAR1 increased the yield of human immunodeficiency virus type 1 (HIV-1) in HEK 293T and 84 COS-7 cells (17, 18); consistent with this finding, knock-down endogenous levels of ADAR1 85 reduced HIV protein accumulation in HEK 293T cells (18). Furthermore, ADAR1 with a catalytic 86 domain deletion failed to enhance viral infectivity and virion release, which indicates that the 87 proviral activity of ADAR1 is regulated by its RNA-editing ability in the context of HIV-1 infection. 88
Independent of RNA editing, ADAR1 also elevates HIV-1 infectivity by interacting with PKR via 89 its RBD, which leads to the inhibition of PKR phosphorylation (19). Similar to observations in 90
HIV-1, measles virus (MV) grew poorly in cells with deficient ADAR1 expression, and that change 91 was accompanied by the suppression of the dsRNA-mediated antiviral response, particularly PKR 92 and IFN regulatory transcription factor-3 (IRF-3) (20). The RNA-editing activity of ADAR1 plays 93 a role not only for RNA viruses but also for DNA viruses that replicate in the nucleus (21, 22), for 94 example, the Herpesviridae family members Kaposi sarcoma-associated virus (KSHV) and 95 Epstein-Barr virus (EBV). A-to-I editing activity eliminated the tumorigenic activity of KSHV, and 96 affected latent infection of EBV by modifying the sequences of the viral kaposin transcript and 97 miR-BART6, respectively (21, 22). For poxvirus, VACV E3 is a potent inhibitor of ADAR1 98 deaminase activity (23). In addition to two highly conserved residues in the Z-DNA binding domain, 99 the RBD at the C-terminus of VACV E3 is essential for ADAR1 antagonism. Nevertheless, the role 100 of ADAR1 in VACV has not been addressed. 101 8 phosphate-buffered saline (PBS) and then infected at the indicated multiplicity of infection (MOI) 120 in DMEM without FBS. After 1 hr of incubation, the infection medium was removed and replaced 121 with DMEM containing 2.5% FBS. 122
Generation of ADAR1 knock out HEK 293T cell line 123
To study the role of ADAR1 play in the course of infection, CRISPR-Cas9 system was applied to 124 inactive ADAR1 expression in HEK 293T cell line. For the ease of monitoring Cas9 expression, 125 mCherry was added into the original plasmid, lentiCRISPR v2 (Addgene plasmid # 52961), 126 followed by P2A sequence (derived from porcine teschovirus-1). The mCherry fragment was 127 amplified by a set of primers (mCherry-infusion-F and mCherry-infusion-R, sequences were listed 128 in Table 1 ), and the amplicon was inserted into the Tth111I site of lentiCRISPR v2 by In-Fusion 129 cloning, resulting in the plasmid, letniCRISPR v2-mCherry. In brief, the annealed oligonucleotide 130 9 experiments, a hemagglutinin (HA) tag was fused to the 3´ end of ADAR1. Briefly, to remove stop 139 codon of ADAR1 from the original ADAR1 plasmid, the region at the 3' end of ADAR1 in the 140 plasmid was initially replaced with a PCR amplicon amplified by a set of primers (ADAR1-KasI-141 F and ADAR1-XhoI-R) using the original ADAR1 plasmid as a template. Subsequently, the 142 annealed oligonucleotides of HA tag (namely, HA-F and HA-R) with compatible ends of restriction 143 enzymes Xho I and Xba I or the entire coding sequence of mCherry amplified from mCherry N1 144 (Clontech, Mountain View, CA, USA) by PCR using the primers mCherry-XhoI-F and mCherry-145
XbaI-R was then inserted into the 3' end of ADAR1, resulting in constructs expressing ADAR1 146 fused with HA tag or mCherry,, respectively. The sequences of the primers and oligonucleotides 147 used in this study were summarized in Table 1 . USA). Fragments with the designated deletions were amplified by specific primers (ΔRBDs-F and 10 using ADAR1-p110-HA as a template. Subsequently, the coding sequences of full-length ADAR1 159 in the ADAR1-p110-HA plasmid were then replaced by the desired fragments, following the 160 manufacturer's instructions. 161
Moreover, the KKxxK motif in each of the three RBDs of ADAR1 was altered to the sequence 162
EAxxA by site-directed mutagenesis using the following primer sets: EAA1-F and EAA1-R; 163 EAA2-F and EAA2-R; and EAA3-F and EAA3-R. Constructs expressing various OV20.0 proteins 164 fused with the FLAG tag were described previously (5). 165
To investigate the A-to-I editing activity of ADAR1, an mCherry reporter construct was made. 166
Briefly, mCherry N1 (Clontech) was digested with BamH I and Bgl II, followed by self-ligation to 167 remove one additional Sal I sequence in the multiple cloning site. The entire sequence of the 168 glutamate B receptor (GluR-B) containing an in-frame amber stop codon (UAG) was assembled 169 from two fragments, which were generated by two sets of oligonucleotides: gluR-B-R/G-fra1-F and 170 gluR-B-R/G-fra1-R; and gluR-B-R/G-fra2-F and gluR-B-R/G-fra2-R. The two annealed GluR-B 171 fragments with comparable sticky ends were then ligated and inserted into the Sal I-linearized 172 mCherry plasmid described above. 173
All fragments were amplified by polymerase chain reaction (PCR) using Phusion® High-Fidelity 174 DNA Polymerase (New England Biolabs, Beverly, MA, USA). The PCR conditions were set as 175 follows: initial denaturation at 98°C for 2 min and 35 cycles consisting of denaturation at 98°C for 176 10 sec, annealing at 55°C for 20 sec and extension at 72°C for 15 sec per 1 kb of the desired 177 11 amplicon, followed by a final extension at 72°C for 7 min. The vectors and inserts were digested 178 with the corresponding restriction enzymes (New England Biolabs). 179
Transfection and immunoprecipitation. Briefly, HEK 293T cells were seeded 1 day before 180 transfection. In general, for a 6-well plate scale, 5 μg of ADAR1 plasmid and 2.5 μg of OV20.0 ice for 30 min, followed by centrifugation at 13,000 rpm for 15 min. One-tenth of the supernatant 190 was saved as the input control. The remaining cell extract was incubated with an anti-FLAG M2 191 affinity gel (Sigma-Aldrich, St. Louis, MO, USA) at 4°C overnight. The next day, the gel was 192 harvested by centrifugation at 13,000 rpm, followed by ten washes with wash buffer (50 mM Tris 193 [pH 7.4] and 150 mM NaCl). Target proteins were then eluted in SDS sample dye and separated by 194 SDS-PAGE, followed by western blot analysis. 12 dsRNA (poly I:C) pull-down assay. Agarose conjugated to poly-cytosine (Sigma-Aldrich) was 196 mixed with 2 volumes of poly-inosine (2 mg/ml) in buffer containing 50 mM Tris (pH 7.0) and 150 197 mM NaCl. To form dsRNA, the mixture was gently mixed on a rotator at 4°C overnight. The 198 agarose beads with dsRNA were then harvested by centrifugation at 1,000 rpm, washed 5 times 199 with wash buffer (50 mM Tris [pH 7.0] and 150 mM NaCl), and resuspended in binding buffer (50 200 mM Tris [pH 7.5], 150 mM NaCl, 1 mM EDTA, and 1% NP-40). 201
The cell lysate expressing the desired proteins was mixed with annealed poly I:C beads on a rotator 202 at 4°C overnight. The next day, the poly I:C beads were collected by centrifugation at 1,000 rpm 203 and then washed ten times with wash buffer. Proteins associated with the dsRNA were eluted in 204 SDS sample dye. 205
Western blot analysis. The samples were separated by SDS-PAGE and then transferred to 206 nitrocellulose paper (NC paper). After blocking in 5% skim milk, the primary antibodies were 207 incubated with the NC paper at 4°C overnight. The next day, the NC papers were washed with PBS 208 plus 0.05% Tween 20 five times, followed by incubation with the corresponding secondary 209 antibody conjugated to horseradish peroxidase (HRP). Protein detection was performed by an 210
ImageQuant LAS 4000 (GE Healthcare, Uppsala, Sweden). The corresponding dilutions of each 211 antibody were as follows: anti-ADAR1 (1:1,000; Santa Cruz Biotechnology), anti-PKR (1:2,000, 212
Abcam), anti-PKR-p (T446; 1:2,000; Abcam), anti-β-actin (1:1,000; Signalway Antibody), anti-213 13 GAPDH (1:1,500; Novus Biologicals), anti-FLAG (1:2,500; Signalway Antibody), anti-HA 214
(1:2,500; Yao-Hong Biotechnology) and anti-OV20.0 (1:2,000) (5). 215
Immunofluorescence assay (IFA). The transfected cells were fixed with 1.875% formaldehyde, 216 permeabilized with 0.5% NP-40, and then incubated with an ADAR1 antibody (sc-73408, 1:100 217 dilution; Santa Cruz Biotechnology) for 1 hr at room temperature. The cells were further incubated 218 with secondary antibodies conjugated to Alexa Fluor 488 (1:5,000 dilution, Invitrogen) for 219 additional 1 hr at room temperature. Wash procedures were applied between each step, with six 220 washes with 1% FBS in PBS, followed by DAPI (4, 6-diamidino-2-phenylindole, at a final 221 concentration of 1 µg/ml, Invitrogen) staining. The cells were examined by an inverted fluorescence 222 confocal microscope (FV1000, Olympus, Tokyo, Japan). Images were acquired by Olympus FV10-223 we suspected that OV20.0 may associate with other DRBPs and influence the fate of virus infection. 230 ADAR1, a cellular DRBP, interacts with PKR and leads to different consequences during viral 231 14 replication (15). Unlike p110, p150 ADAR1 was not obviously induced in ORFV infection (data 232 not shown), only p110 was represented in this study. To determine the binding domain involved in 233 the OV20.0-ADAR1 interaction, a set of OV20.0 plasmids was constructed to express the wild-234 type form (WT, encoding two isoforms), the full-length isoform only (K20), the N-terminally 235 truncated short form (sh20), or the C-terminally truncated form (ΔC) of OV20.0 (Fig. 1A) . OV20.0 236 and all of its variants were detected by a FLAG antibody ( Fig. 1B; input) . Moreover, both isoforms 237 (K20 and the N-terminal truncation sh20) could pull down endogenous ADAR1 ( Fig. 1B; left Next, a recombinant ORFV expressing FLAG-tagged OV20.0 (5) was used to verify the association 242 between OV20.0 and ADAR1 in the context of ORFV infection. HEK 293T cells were infected 243 with ORFV-FLAG at an MOI of 1, and the cell lysate was harvested at 24 hr post infection (hpi), 244 followed by FLAG-IP. Consistent with results of transient expression ( Fig. 1B) , endogenous 245 ADAR1 was associated with FLAG-tagged OV20.0 produced during ORFV infection (Fig. 1C) . 246 247 Cellular distribution of OV20.0 and ADAR1. 248
Cellular distribution of OV20.0 isoforms has been described (5); K20 is a nuclear protein, and sh20 249 expresses in both nuclear and cytoplasm. As OV20.0 associates with ADAR1, whether that protein-250 protein interaction can lead to an alteration of protein cellular distributions is of interest. To monitor 251 15 subcellular localization, ADAR1 and OV20.0 were expressed with an mCherry or eGFP tag at their 252 C-terminus, respectively. As observed for endogenous ADAR1, ADAR1-mCherry was expressed 253 as a speckled pattern in the nucleus (left and right panels in Fig. 2A, respectively) . Further, the 254 integrity of the ADAR1-mCherry fusion protein and the expected size of approximately 150 kDa 255 were confirmed by western blot analysis ( Fig. 2A, lane 2 indicated with an arrow) . 256
When K20-eGFP was expressed with ADAR1-mCherry, the proteins colocalized in the nucleus 257 ( Fig. 2B) . Approximately, ADAR1 colocalization was observed in 50% (53 out of 106), or 64% 258 (106 out of 166) of cells overexpressing K20-eGFP or sh20-eGFP, respectively. Interestingly, in 259 the presence of sh20-eGFP, a portion of the ADAR1-mCherry signal shifted from the nucleus to 260 the cytoplasm and colocalized with sh20-eGFP in the cytoplasm (Fig. 2B , indicated with white 261 arrows). In contrast, ΔC-eGFP was expressed throughout the cells; however, it was not particularly 262 colocalized with ADAR1 in the nucleus. Collectively, both K20 and sh20 colocalized with ADAR1 263 in a transient expression system in HEK 293T cells. 264 265 RBD1 of ADAR1 is essential for the interaction with OV20.0. 266
To identify the region of ADAR1 that contributes to the OV20.0 interaction, a set of ADAR1 267 constructs with deletion of the main functional domains (Fig. 3A) , including the Zβ DNA binding 268 domain (ΔZβ), all RBDs (ΔRBDs), and the deaminase catalytic domain (ΔCat) were generated. The 269 results of FLAG-IP showed that in the absence of the Z or catalytic domains, ADAR1 still 270 associated with OV20.0. However, when ADAR1 lacked all RBDs, the interaction between OV20.0 271 16 and ADAR1 was greatly reduced (Fig. 3B, left panel) . 272
Next, we further examined which RBD domain in ADAR1 is important for the interaction. OV20.0 273 with a FLAG tag and ADAR1 with deletions of individual RBDs (ΔR1, ΔR2, or ΔR3) were 274 transiently expressed in HEK 293T cells, followed by FLAG-IP. The data demonstrated that the 275 deletion of R2 of the three RBDs did not have effect on the ADAR1-OV20.0 interaction (Fig. 3C) . 276
However, the absence of the first RBD of ADAR1 significantly decreased the binding between 277 OV20.0 and ADAR1 (Fig. 3D ). In conclusion, the RBDs of ADAR1, especially the first RBD, were 278 crucial for the OV20.0-ADAR1 interaction. 279 280 dsRNA binding ability of ADAR1 is not necessary for the interaction between OV20.0 and 281
ADAR1. 282
According to a previous report, OV20.0 interacts with and disrupts the function of other DRBPs, 283 such as PKR, in the absence of dsRNA (6). We next investigated whether the dsRNA binding ability 284 of ADAR1 is involved in the interaction with OV20.0. Therefore, an ADAR1 mutant (EAA) that 285 is defective in dsRNA binding ability (25, 26) was used to address this issue. A triple-nucleotide 286 point mutation (EAxxA) was introduced in each RBD of ADAR1 to replace the original dsRNA 287 binding motif (KKxxK). First, as with previous findings (25, 26), the EAxxA mutations in the three 288
RBDs indeed impeded the dsRNA binding ability of ADAR1 in a poly I:C pull-down assay (Fig.  289   4A) . Then, FLAG-IP was performed to investigate the interaction between OV20.0 and the EAA 290 mutant ADAR1; the data showed that OV20.0 associated with WT ADAR1 and the EAA mutant 291 to similar extents (Fig. 4B ). In conclusion, we found that the dsRNA binding ability of ADAR1 is 292 not essential for the interaction of ADAR1 with OV20.0. 293 294 OV20.0 disrupts the A-to-I editing activity of ADAR1. 295
The A-to-I editing activity of ADAR1 has been shown to enhance or prevent viral replication in a 296 cell-and virus-dependent manner; however, it has only been characterized for a few viruses (27) . 297
At present, the impact of the association of OV20.0 on ADAR1 remains unclear. To address this 298 issue, an mCherry reporter assay was established to measure the A-to-I editing activity of ADAR1. 299
The sequence of the glutamate B receptor (GluR-B) containing an in-frame amber stop codon (UAG) 300 (28) was inserted into the mCherry coding region near its C-terminus, resulting in the translation of 301 a C-truncated product (Fig. 5A, unedited) . In the presence of ADAR1 A-to-I editing, the stop codon 302 UAG could be converted to UIG, leading to the expression of full-length mCherry (Fig. 5A, edited) . 303
As shown in Fig 5B, in the absence of ADAR1, only truncated mCherry was expressed (Fig 5B,  304 lane 1), while ADAR1 over-expression led to the translation of full-length mCherry in a dose-305 dependent manner (Fig. 5B, lane 2-4) . 306
Compared with ADAR1 alone (Fig. 5C, lane 2) , the coexistence of OV20.0 significantly reduced 307 the A-to-I editing activity of ADAR1 (lane 4 in Fig 5C, and Fig 5D) . Noticeably, the expression of 308 OV20.0 alone had no effect on A-to-I editing ( Fig 5C, lane 3) . These results suggested that OV20.0 309 interrupted the A-to-I editing activity of ADAR1. 310
ADAR1 plays a proviral role in ORFV infection. 311 18
To date, the role of ADAR1 in ORFV replication remains unknown. Moreover, both ADAR1 and 312 OV20.0 interfere with PKR activation, and it is of interest to investigate the effect of ADAR1 on 313 PKR signaling in the presence of viral OV20.0. 314
First, the effect of ADAR1 on PKR phosphorylation was verified. Compared with mock treatment, 315 PKR activation was indeed stimulated by the transfection of synthetic dsRNA, poly I:C (Fig. 6A,  316 lane EV). However, PKR activation was lower in cells overexpressing ADAR1 than in cells 317 transfected with empty vector (EV) (Fig. 6A, right panel) . Moreover, the deletion of the RBDs 318 slightly restored PKR activation compared with WT ADAR1 (Fig. 6B ). Next, since OV20.0 and 319 ADAR1 associate with each other and both proteins are able to inhibit PKR phosphorylation, we 320 further investigated whether the presence of OV20.0 influences the inhibitory effect of ADAR1 on 321 PKR activation. As shown in Fig 6C, compared with the positive control (PC), OV20.0 suppressed 322 PKR phosphorylation (PC vs. lane 1), and the coexistence of ADAR1 further inhibited PKR 323 activation (Fig. 6C, lane 1 vs. lane 2-4) . 324
Furthermore, as OV20.0 associated with both PKR and ADAR1, it is unclear whether there is a 325 binding hierarchy of OV20.0 with these two cellular proteins. To address this question, OV20.0-326 FLAG was coexpressed with increasing amounts of ADAR1, followed by FLAG-IP. The results 327 demonstrated that similar amounts of PKR interacted with OV20.0, even with gradually increasing 328 ADAR1 levels (Fig. 6D ). This finding suggested that ADAR1 did not compete with the interaction 329 between OV20.0 and PKR. 330
Finally, we investigated the impact of ADAR1 on ORFV infection. ADAR1-HA or ADAR1-331 19 mCherry and the HA or mCherry vector, as a negative control, were transfected into HEK 293T 332 cells for 24 hr, followed by infection with recombinant ORFV expressing eGFP (5). The results 333 showed that the overexpression of WT ADAR1 led to increased virus-encoded eGFP levels (Fig.  334   7A) . Interestingly, the elevated virus-encoded protein was significantly diminished when the cells 335 expressed ADAR1 with a deletion of all three RBDs (Fig. 7A, right panel) , suggesting that ADAR1 336 played a supportive role through the contribution of its RBDs during ORFV infection. 337
Despite various effects of ADAR1 on virus replication, it has been reported ADAR1 enhances viral 338
infection through the inhibition of PKR activity (16). In cells overexpressing ADAR1 during ORFV 339 infection, we monitored the activation of PKR signaling and noticed that increased viral OV20.0 340 levels are correlated with a significantly lower PKR activation status (Fig 7B, middle middle) . 341
Overall, with ADAR1 over-expression, the viral yield of ORFV was increased by approximately 4 342 folds ( Fig 7B, right panel) . To further confirm the role of ADAR1, 293T cells with ADAR1 343 expression was knocked out by means of CRISPER technique. As shown in Fig 7C, in the absence 344 of ADAR1 expression (KO), ORFV structural protein F1 level was lower than that in cells with 345 endogenous ADAR1 (WT). 346 347 20
Discussion 348
This study identified ADAR1 as a novel dsRNA binding protein (DRBP) that interacts with OV20.0 349 and enhances the replication of ORFV. According to previous reports, the RBD of OV20.0 mediates 350 its interactions with both PKR and PACT, leading to the inhibition of PKR activation (5, 6). 351
Similarly, OV20.0 and ADAR1 interact with each other via their RBD regions. In particular, the 352 first RBD domain in ADAR1 (R1) is not only critical for the interaction with OV20.0 but also 353 essential for the dimerization of ADAR1 (29). It is possible that OV20.0 association impairs the 354 formation of the ADAR1 homodimer, which is the functional conformation (e.g., A-to-I editing 355 activity). By using the EAA mutant ADAR1 with deficient dsRNA binding ability (25, 26), we 356 further demonstrated that dsRNA binding ability of ADAR1 is not required for the OV20.0-ADAR1 357 interaction, which is consistent with the scenario reported for the PKR and PACT interaction (6). 358
Similarly, OV20.0 directly interacts with PKR without the aid of dsRNA (6). Moreover, we found 359 that ADAR1 is not able to compete with PKR for the interaction of OV20.0, implicating that 360 OV20.0 favors binding to PKR over ADAR1. However, whether these interactions are bridged via 361 either PKR or ADAR1 requires further investigations due to the multiple interactions among these 362
DRBPs, OV20.0, PKR, and ADAR1. 363 OV20.0 was expressed as two isoforms, and both full-length OV20.0 and its N-terminally truncated 364 short form (sh20) colocalized with ADAR1 (Fig. 2B) . In our previous report, sh20 was mainly 365 expressed in the cytoplasm due to the lack of a putative nuclear localization signal (NLS). 366 21 Noticeably, a small portion of sh20.0 was colocalized with ADAR1 in nuclear domains, possibly 367 nucleoli. Although ADAR1 largely remains in the nucleus, a dynamic subcellular distribution of 368 ADAR1 has been reported; the protein shuttles between the cytoplasm, nucleus, and nucleolus (30, 369 31). It is worth noting that OV20.0 does not contain a nucleolus localization signal. Since ADAR1 370 localizes in the nucleolus (31-33), it is likely that the redistribution of both isoforms into subnuclear 371 domains could be mediated by the association with ADAR1 ( Fig 2B) . Furthermore, ADAR1 is also 372 translocated from the nucleus to the cytoplasm in a subset of cells coexpressing sh20 (Fig. 2) , 373
suggesting that intermolecular interactions may affect the localization of both ADAR1 and sh20. 374
Barrauda and colleagues reported that the nuclear transportation of ADAR1 is aided by the nuclear 375 import receptor transportin-1 (TRN1), which interacts with the region where the NLS overlaps with 376 the RBD (namely, the RBD-NLS) of ADAR1 (34). Therefore, we postulate that the association of 377 sh20 with ADAR1 might interrupt the binding between the RBD-NLS of ADAR1 and TRN1, which 378 in turns leads to the cytoplasmic retention of ADAR1. 379 ADAR1 modulates host innate immunity against viral pathogens via its RNA-editing activity and 380 that in turns inhibits PKR activation (15). Very recently, Chung and colleague further identified 381 that not only dsRNA binding, also catalytic domain of ADAR1 is required for efficiently 382 downregulates hyperactivation of PKR induced by endogenous dsRNA(26). In addition, the 383 contribution of ADAR1 on RNase L-mediated apoptosis triggered by dsRNA was also reported (4). 384
On the other hand, A-to-I editing activity potentially alters the genetic code or disrupts RNA 385 structures, which can lead to either enhanced or reduced virus growth (35). For instance, several 386 viral DRBPs, including nonstructural protein 1 (NS1) of influenza A virus and NS3 of Dengue virus, 387
were found to interact with ADAR1 and improve its A-to-I editing activity, which is correlated with 388 enhanced viral replication (36). Nonetheless, the RNA replication of human hepatitis C virus (HCV) 389 was increased in ADAR1-deficient cells, indicating that ADAR1 plays a role in limiting viral 390 infection by specifically eliminating HCV RNA (37). Accordingly, the role of ADAR1 in viral 391 infection as either an antiviral or proviral factor is dependent on the involved viruses and cell types 392 (27). Previous reports found that the formation of a homodimer of ADAR1 via its RBDs is 393 important for its RNA-editing activity (25). Moreover, mutations of key residues in the third RBD 394 (R3) in ADAR1 impaired both dsRNA-binding ability and catalytic activity (38). Collectively, 395 these findings demonstrate that the functional conformation, dsRNA-binding ability, and deaminase 396 activity of ADAR1 are key components that contribute to the A-to-I editing of ADAR1. The study 397 presented herein demonstrated that OV20.0 suppresses ADAR1-dependent A-to-I editing activity 398 ( Fig 5) . Since the RBDs of ADAR1 are associated with and therefore preoccupied by OV20.0, the 399 suppression of ADAR1 RNA editing activity could be due to the loss of its RNA binding ability 400 or/and the inability to form functional homodimers. Furthermore, OV20.0, as a dsRNA binding 401 protein, could compete for dsRNA substrate with ADAR1. 402
Vaccinia virus E3, an ortholog of OV20.0, suppressed the A-to-I editing of ADAR1 (23); however, 403 at present, the potential role of ADAR1 in the replication of vaccinia virus, ORFV, or other 404 members of the Poxviridae remains unclear. In addition to its dsRNA editing function, ADAR1 405 influences viral replication by interacting with PKR, which leads to the inhibition of its 406 23 phosphorylation (16, 19) . For efficient replication, many viruses encode gene products that target 407 PKR or its downstream effector, illustrating the importance of PKR signaling for antiviral defense 408 (39). ADAR1 inhibits PKR via several strategies, including the sequestration of dsRNA and the 409 prevention of PKR activation through a direct interaction, and hence exerts a proviral activity (19, 410 20, 30). According to one previous report (19) and our data, the RBDs of ADAR1 are required for 411 suppressing PKR phosphorylation. This observation suggests that ADAR1 competes for binding of 412 the PKR activator, dsRNA, via its RBDs, which are also a potential domain by which ADAR1 413 contacts and forms an inactive dimer with PKR, leading to the inhibition of PKR activation. The 414 effect of ADAR1 on PKR activation is well studied in the context of retrovirus infection (19, 40) . 415
It was shown that both full-length ADAR1 and a mutant ADAR1 with a catalytic domain deletion, 416 rather than a truncation mutant in the RBDs, can restore HIV production inhibited by PKR. The 417 results demonstrated that the attenuation of the inhibitory effect of PKR on HIV requires the RBDs 418 of ADAR1 but not its deaminase function (19) . Consistent with this finding, another study showed 419 that the expression of wild-type and editing-deficient ADAR1 leads to comparable increases in 420
human T-cell leukemia virus (HTLV) release and viral protein expression (40). Further, the level 421 of PKR activation is inversely correlated with the level of ADAR1 expression. Collectively, the 422 proviral effect of ADAR1 on HTLV is mediated by the inhibition of PKR phosphorylation and is 423 independent of its editing activity. These data suggest that the impact of ADAR1 on viral replication 424 could be variable owing to the versatile activity of ADAR1 (an RNA modifier, a DRBP) and the 425 dynamic interactions among the DRBPs (PKR, ADAR1, and viral proteins). 426 24 In conclusion, several novel findings were revealed in this study. First, the association of OV20.0 type OV20.0, Kozak OV20.0 (K20), short form OV20.0 (sh20), C-terminus deletion OV20.0 577 (ΔC), and FLAG empty vector (EV, as a negative control for the IP procedure) were transfected 578 individually into HEK 293T cells, followed by IP with an FLAG-antibody (FLAG-IP). (C) HEK 579
293T cells were infected with a recombinant eGFP reporter ORFV expressing FLAG-tagged 580 OV20.0 at an MOI of 1 for 24 hr, followed by FLAG-IP. 
